Quick Facts About Risdiplam

Feature	Detail
Generic Name	Risdiplam
Indian Generic Brand	Natsmart® (Natco Pharma Ltd)
Drug Class	SMN2 Splicing Modifier
Form Available	Oral solution (liquid, taken daily)
Who Can Take It	All ages from birth onwards
How Often	Once daily, with or without food
FDA Approval	August 2020 (oral solution) \| February 2025 (tablet)
DCGI India Approval	October 2020

Risdiplam for Spinal Muscular Atrophy (SMA) — What Patients and Families Need to Know

Spinal Muscular Atrophy is one of the cruelest diseases a family can face. It steals a child’s ability to move, breathe, and grow sometimes from the very first months of life. But today, for the first time in medical history, there is an oral medicine that addresses the root cause of SMA: Risdiplam.

For families in the USA paying over $150,000 a year, or for those in countries where the medicine is simply unavailable, India now offers a solution. Natco Pharma’s Natsmart a CDSCO-approved generic version of Risdiplam contains the exact same active molecule and is available at a fraction of the global price.

This page explains everything you need to know: what the disease is, how Risdiplam works, what makes Natsmart the same as branded, and how international patients may access it through licensed facilitators like Delightaid Health.

1. Understanding Spinal Muscular Atrophy — The Disease Risdiplam Treats

What Is SMA?

Spinal Muscular Atrophy is a rare genetic disease. It affects the motor neurons the nerve cells that tell your muscles to move. When these nerve cells stop working properly, muscles throughout the body weaken and waste away over time.

SMA is caused by a mutation or deletion in a gene called SMN1 (Survival Motor Neuron 1). This gene is responsible for producing a protein — called SMN protein — that motor neurons need to survive. Without enough SMN protein, motor neurons die, and muscles progressively lose function.

SMA affects approximately 1 in every 6,000–10,000 newborns worldwide. It is the leading genetic cause of infant mortality globally. Yet until 2020, there was no oral medicine that could address its root cause.

The Four Types of SMA

Type	Onset Age	Key Feature	Without Treatment
Type 1 (Werdnig-Hoffmann)	0–6 months	Cannot sit unaided	Death / ventilator by age 2
Type 2	6–18 months	Can sit, cannot stand	Wheelchair-dependent; shorter lifespan
Type 3 (Kugelberg-Welander)	After 18 months	Can walk, progressively weakens	Reduced mobility over time
Type 4 (Adult-onset)	After age 21	Mild progressive weakness	Mostly normal lifespan

Every type of SMA shares one underlying cause: too little SMN protein. This is exactly what Risdiplam targets.

What SMA Patients and Families Go Through: The Real Pain

Living with SMA is not just a medical experience. It is an emotional, financial, and daily physical challenge:

Parents watch their baby miss milestones — unable to lift their head, roll over, or sit up while other babies their age run and play.
Feeding difficulties and breathing problems compound the suffering, especially in Type 1. Many infants require feeding tubes and ventilators.
For older patients, every year can bring loss of the ability to walk, use hands, or live independently.
The financial burden is catastrophic: International branded Risdiplam costs approximately ₹6.2 lakh per bottle in India, and over $150,000 per year in the USA. An adult patient needs 2–3 bottles per month annual costs between ₹60–72 lakh in India or $150,000+ in the USA.
Insurance denials and access gaps leave many families without treatment even in countries where the drug is approved.
The emotional weight of a progressive disease with no cure creates profound anxiety for patients and caregivers alike.

2. What Is Risdiplam? The Medicine That Changed SMA Treatment

Risdiplam in Simple Terms

Risdiplam (Indian generic: Natsmart® by Natco Pharma) is the world’s first oral, at-home medicine that addresses the underlying cause of SMA.

Most people with SMA are missing or have a broken SMN1 gene. However, they do have a backup gene called SMN2. The problem is that SMN2 produces faulty, non-functional protein most of the time only about 10–15% of its protein actually works.

Key Advantage:

Risdiplam works throughout the entire body in the spinal cord, brain, and peripheral tissues because it is taken orally and travels through the bloodstream. This body-wide reach is one of its most important clinical advantages over injection-based therapies.

3. Natsmart vs Evrysdi — Is It the Same Medicine? A Clear Answer.

This is the most important question for patients considering Indian generic Risdiplam. Let us answer it clearly and honestly.

✅ YES — Natsmart Contains the Identical Active Molecule as Evrysdi

Natco Generic Risdiplam (Natsmart) and branded Risdiplam are the same medicine at the molecular level. The mole There is no difference in the active substance.

Why You Can Be Confident — Four Reasons

Identical Active Pharmaceutical Ingredient (API)

Both have the same chemical compound. The molecule that enters your bloodstream and modifies SMN2 splicing is chemically identical in both products. There is no difference in the active substance.

Manufactured by a Globally Recognised Pharma Company

Natco Pharma Limited is not a small or unknown company. It is a Hyderabad-based pharmaceutical company with USFDA-inspected manufacturing facilities, a decades-long track record of manufacturing oncology generics for global markets including the USA, WHO-GMP compliance, and approved generic launches in the USA with 180-day exclusivity periods.

Approved by CDSCO (India’s Drug Regulator)

The Central Drugs Standard Control Organisation (CDSCO) India’s equivalent of the US FDA — reviewed and approved Natsmart before it was allowed to be sold. CDSCO mandates bioequivalence studies and quality standards ensuring the generic performs the same way as the originator.

The Delhi High Court Validated It — The Dispute Was About Patents, Not the Molecule

The landmark Delhi High Court judgment in October 2025 was fought because both parties agreed the compound is risdiplam. The entire dispute was about patent rights — not about whether the molecules are different. The court’s ruling that Natco could proceed confirms there is no dispute about the molecule itself.

4. About Natco Pharma. Why Trust Natsmart?

Who Is Natco Pharma?

Natco Pharma Limited is one of India’s most respected specialty pharmaceutical companies, founded in 1981 and headquartered in Hyderabad, Telangana. With a global reputation as a champion for affordable access to life-saving medicines.

Natco Pharma’s Track Record — A Champion for Patient Access

India’s First Compulsory License: Natco won India’s first compulsory license for the cancer drug sorafenib (Nexavar, Bayer) in 2012 — reducing cost by 97% — and established the precedent that public health outweighs patent monopoly.
US Market Launches: Natco has launched multiple oncology generics in the US market with 180-day exclusivity, proving it meets the world’s highest pharmaceutical quality standards.
WHO-GMP Compliance: Natco’s facilities operate under WHO Good Manufacturing Practice standards, ensuring consistent quality across all medicine batches.
Challenging Evergreening: Natco has successfully challenged numerous patents where it believed patients were being denied access due to patent evergreening practices.

Natsmart: Natco’s Landmark Gift to India’s SMA Community

Natco Pharma’s launch of Natsmart (Risdiplam oral solution) is a watershed moment for India’s rare disease community. For years, Indian SMA families faced a devastating paradox: the only oral treatment for their child’s condition was approved in India but priced at ₹72 lakh per year far beyond the reach of the vast majority of Indian families.

For international patients in the USA, UK, UAE, China, Australia, and other countries, Natsmart represents a legitimate, quality-assured pathway to access risdiplam therapy at up to 98% lower cost than branded Risdiplam.

Impact for SMA Patients:

Branded risdiplam: ₹72 lakh per year → Natsmart (Natco): ₹5 lakh per year Health activists estimate government bulk purchases could reduce cost to ₹3.1 lakh per year — meaning existing government rare disease financial support (₹50 lakh) could sustain a patient’s treatment for over 16 years.

6. How Does Risdiplam Help Patients? Clinical Evidence

FIREFISH Trial — Type 1 SMA (Infants)

The FIREFISH study tested risdiplam in infants with Type 1 SMA — the most severe form, where babies typically do not survive past age 2 without treatment.

Outcome Measure	Result with Risdiplam
Survival without permanent ventilation	81%+ after 23+ months of treatment
Motor milestones achieved	Majority sat, many stood — milestones never reached without treatment
Feeding & swallowing	Children demonstrated oral feeding ability
Cognitive skills	Normal for age — no SMA impact on cognition
Pre-symptomatic (RAINBOWFISH 2024)	None required permanent ventilation when treated before symptoms

SUNFISH Trial — Type 2 and 3 SMA (Older Children & Adults)

The SUNFISH study tested risdiplam in patients with later-onset SMA (Types 2 and non-ambulant Type 3) — ages 2–25 years. Final 5-year data was presented in March 2025.

Motor function improvements achieved in the first year were maintained over 5 years of continuous treatment.
Untreated patients experienced significant motor function decline — treated patients did not.
Risdiplam was safe and well-tolerated across years of continuous use with no new safety signals.

7. Dosage and How to Take Risdiplam

Risdiplam is always prescribed and dosed by a specialist neurologist. The dose depends on the patient’s age and body weight:

8. Side Effects — What Patients and Families Should Know

Risdiplam is generally well tolerated. In clinical trials spanning up to 5 years, the most commonly reported side effects included:

Common Side Effects (Most Patients)

Fever
Diarrhoea
Rash
Mouth ulcers (aphthous ulcers)
Joint pain (arthralgia)
Urinary tract infections
Upper respiratory tract infections

Additional Side Effects in Infants

Constipation
Vomiting
Pneumonia

9. Price Comparison — Risdiplam Globally vs India

Country / Source	Monthly Cost (Est.)	Annual Cost (Est.)
USA (Risdiplam branded)	~$13,000–$17,000	~$150,000–$200,000
India (Natsmart — Natco Pharma)	~₹40,000–48,000	~₹5 lakh (97% saving vs branded India)
International patients via facilitator	~$180–$260 per bottle	~98% saving vs branded USA price

Note: Dosing varies by age and weight. Cost figures are indicative. Please contact Delightaid Health for current pricing and availability.

10. How International Patients Can Access Risdiplam from India

As a medical facilitator, Delightaid Health helps international patients access Natsmart (generic risdiplam) from India through trusted suppliers.

What You Need

A valid prescription from a registered neurologist or specialist
Diagnosis confirmation (genetic test reports confirming SMA — SMN1 deletion/mutation)
Patient ID proof issued by your government
Import permit, if required by your country.

Countries Where Personal Importation Is Generally Permitted

USA, United Kingdom, UAE, Australia, China, and many others. Regulations vary by country please contact us for country-specific guidance.

What Delightaid Health Does For You

Prescription & document verification — all documents verified by registered pharmacists
Authentic sourcing — Natsmart sourced from Natco Pharma’s authorised supply chain only
Import documentation guidance — country-specific support for all paperwork
International shipping — delivered to your address
Transparent pricing — no hidden charges. Clear breakdown of medicine cost, facilitator fee, and shipping

⚠️ Important Note:

Delightaid Health is a healthcare facilitator — we connect patients with licensed pharmaceutical suppliers. We are not a pharmacy or drug manufacturer. All medicines are dispensed against valid prescriptions verified by registered pharmacists. We do not sell medicines we facilitate access.

11. Frequently Asked Questions — Risdiplam & Natsmart

Q1: Is Natsmart the exact same medicine as Branded?

Yes. Natsmart and Inventor medicine contain the same active ingredient risdiplam at the same molecular level. Natsmart is manufactured by Natco Pharma, a USFDA-inspected company with regulatory approvals across global markets.

Q2: Is Risdiplam a cure for SMA?

Risdiplam is a disease-modifying therapy not a cure. It increases SMN protein production on an ongoing basis, which helps slow or halt disease progression and can allow patients to achieve and maintain motor milestones. Treatment must continue daily for it to remain effective. Stopping treatment may result in loss of motor function gains.

Q6: How much does Natsmart cost compared to US branded?

Natco Pharma’s Natsmart is priced at approximately ₹15,900 per bottle (60mg oral solution), compared to branded Risdiplam at approximately ₹6.2 lakh per bottle in India — a 97% reduction. For international patients, Indian generic risdiplam accessed through licensed facilitators can represent up to 98% cost savings compared to branded prices in the USA.

⚕️ Medical Disclaimer

The information provided in this document is for educational purposes only and is intended to help patients and caregivers understand Risdiplam and their treatment options. It does not constitute medical advice, diagnosis, or a recommendation to start, stop, or change treatment. Risdiplam (Natsmart) is a prescription-only medicine. It must only be prescribed and supervised by a qualified neurologist or specialist experienced in the treatment of Spinal Muscular Atrophy. Delightaid Health is a healthcare facilitator. We connect patients with authorised suppliers and guide the import process. We are not a pharmacy, drug manufacturer, or medical provider. All medicines are dispensed against valid prescriptions. Prices mentioned are indicative and subject to change.